EA200701017A1 - Применение рибозы-цистеина для лечения гипоксии - Google Patents

Применение рибозы-цистеина для лечения гипоксии

Info

Publication number
EA200701017A1
EA200701017A1 EA200701017A EA200701017A EA200701017A1 EA 200701017 A1 EA200701017 A1 EA 200701017A1 EA 200701017 A EA200701017 A EA 200701017A EA 200701017 A EA200701017 A EA 200701017A EA 200701017 A1 EA200701017 A1 EA 200701017A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hypoxia
rybosis
cybotine
treatment
application
Prior art date
Application number
EA200701017A
Other languages
English (en)
Other versions
EA014076B1 (ru
Inventor
Герберт Т. Нагасава
Original Assignee
Биосьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биосьютикалс, Инк. filed Critical Биосьютикалс, Инк.
Publication of EA200701017A1 publication Critical patent/EA200701017A1/ru
Publication of EA014076B1 publication Critical patent/EA014076B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

Охватывается терапевтический способ, заключающийся в лечении млекопитающего, страдающего гипоксией, некоторым количеством 2(R,S)-D-рибо-(1',2',3',4'-тетрагидроксибутил)тиазолидин-4(R)-карбоновой кислоты (RibCys) или её фармацевтически приемлемой соли, эффективным для поддержания, восстановления или повышения как уровней АТФ, так и уровней глутатиона (GSH) в указанной ткани.
EA200701017A 2004-11-17 2005-11-16 Применение рибозы-цистеина для лечения гипоксии EA014076B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/990,933 US20060105972A1 (en) 2004-11-17 2004-11-17 Method to enhance delivery of glutathione and ATP levels in cells
PCT/US2005/041458 WO2006055597A1 (en) 2004-11-17 2005-11-16 Use of ribose-cysteine to treat hypoxia by enhancing delivery of glutathione and atp levels in cells

Publications (2)

Publication Number Publication Date
EA200701017A1 true EA200701017A1 (ru) 2007-10-26
EA014076B1 EA014076B1 (ru) 2010-08-30

Family

ID=35759146

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701017A EA014076B1 (ru) 2004-11-17 2005-11-16 Применение рибозы-цистеина для лечения гипоксии

Country Status (14)

Country Link
US (4) US20060105972A1 (ru)
EP (1) EP1824481B1 (ru)
JP (1) JP2008520681A (ru)
KR (1) KR20070095900A (ru)
CN (1) CN101060840A (ru)
AU (1) AU2005307885B2 (ru)
BR (1) BRPI0516814A (ru)
CA (1) CA2587616C (ru)
DK (1) DK1824481T3 (ru)
EA (1) EA014076B1 (ru)
ES (1) ES2390228T3 (ru)
MX (1) MX2007005835A (ru)
PL (1) PL1824481T3 (ru)
WO (1) WO2006055597A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105972A1 (en) * 2004-11-17 2006-05-18 Nagasawa Herbert T Method to enhance delivery of glutathione and ATP levels in cells
JP4982755B2 (ja) * 2006-06-27 2012-07-25 国立大学法人 長崎大学 高速液体クロマトグラフィーによる糖及び類縁アルデヒド化合物の絶対配置決定法
US8685951B2 (en) * 2007-03-27 2014-04-01 The Board Of Trustees Of The University Of Arkansas Compositions and methods for cytoprotection
CN102387805A (zh) * 2008-04-02 2012-03-21 生物能公司 核糖在对于急性心肌梗塞的第一反应中的用途
TW201201712A (en) * 2010-01-28 2012-01-16 Max International Llc Compositions comprising sugar-cysteine products
TW201202209A (en) * 2010-01-28 2012-01-16 Max International Llc Methods of preparing thiazolidines
WO2011149835A1 (en) * 2010-05-24 2011-12-01 Max International, Llc Compositions and beverages comprising nutrients, vitamins, sugars, cysteine, and/or sugar-cysteine products
US20140348811A1 (en) * 2011-07-27 2014-11-27 Max International, Llc Compositions comprising sugar-cysteine products
CN107708711A (zh) * 2015-05-22 2018-02-16 艾尔牛奶有限公司 β‑酪蛋白A2和抗氧化能力
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1120033B (it) 1979-10-05 1986-03-19 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale
US4335210A (en) * 1981-02-11 1982-06-15 Cornell Research Foundation Method of producing L-cysteine
US4647571A (en) 1981-02-11 1987-03-03 Cornell Research Foundation Cysteine delivery composition
US4605644A (en) * 1985-02-07 1986-08-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia employing ribose and adenine
US4719201A (en) * 1985-02-07 1988-01-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia
US4736060A (en) 1985-08-06 1988-04-05 Nippon Rikagakuyakuhin Co., Ltd. Method for optical resolution of DL-cysteine and (R,S)-1-(1-naphthyl) ethylamine
JPS63152325A (ja) * 1986-08-20 1988-06-24 Yamanouchi Pharmaceut Co Ltd 脳虚血症予防治療剤
US4868114A (en) * 1987-08-05 1989-09-19 Regents Of The University Of Minnesota Method for elevating glutathione levels
US5095027A (en) * 1991-02-28 1992-03-10 Clintec Nutrition Co. Method for treating reperfusion injury employing L-2-oxothiazolidine-4-carboxylic acid
US5631234A (en) * 1991-04-15 1997-05-20 Teijin Limited Method for treating ischemia-reperfusion tissue injury
KR0159949B1 (ko) * 1991-04-15 1998-12-01 이다가끼 히로시 허혈-재관류 조직 장해, 부정맥, 및 활성산소 및 자유 라디칼에 의해 야기된 폐장해의 예방 또는 치료제
US5292538A (en) 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
JPH10139665A (ja) * 1996-09-12 1998-05-26 Sankyo Co Ltd トログリタゾンを含有するグルタチオン還元酵素活性増強剤
EP1021177A4 (en) 1997-02-04 2002-05-15 John V Kosbab COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF VASCULAR DEGENERATIVE DISEASES
US6730336B2 (en) 1998-01-30 2004-05-04 The Procter & Gamble Co. Fortified beverages with improved texture and flavor impact at lower dosage of solids
US6218366B1 (en) * 1998-06-19 2001-04-17 Bioenergy, Inc. Method for raising the hypoxic threshold
US7153503B1 (en) 1998-12-19 2006-12-26 Janeel Henderson Comprehensive dietary supplement
US6534480B2 (en) * 1999-06-17 2003-03-18 Bioenergy Inc. Compositions for increasing energy in vivo
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US6964969B2 (en) 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US6881425B2 (en) 2001-08-31 2005-04-19 Council Of Scientific And Industrial Research Custom made herbal health promotive formulation for females/expectant mothers
US6572899B1 (en) 2002-07-03 2003-06-03 Vitacost.Com, Inc. Memory loss treatment formulation
US7455857B2 (en) 2003-04-08 2008-11-25 Janeel Henderson Energy generating composition
GB0319463D0 (en) 2003-08-20 2003-09-17 Givaudan Sa Compounds
US20050100537A1 (en) 2003-11-10 2005-05-12 Evans Gregory S. Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals
US20060105972A1 (en) 2004-11-17 2006-05-18 Nagasawa Herbert T Method to enhance delivery of glutathione and ATP levels in cells
US8962058B2 (en) 2005-11-23 2015-02-24 The Coca-Cola Company High-potency sweetener composition with antioxidant and compositions sweetened therewith
KR101661246B1 (ko) 2006-02-10 2016-09-29 마나테크, 인코포레이티드 흡수 및 생물학적 이용 증진을 위한 완전 천연 종합 비타민 및 종합 미네랄 건강 보조제
US8685951B2 (en) 2007-03-27 2014-04-01 The Board Of Trustees Of The University Of Arkansas Compositions and methods for cytoprotection
WO2010033915A2 (en) 2008-09-19 2010-03-25 Unicity International Inc. Method of controlling blood sugar levels, insulin levels, cholesterol levels, body fat levels, and body weight by administering a nutrient fiber matrix
TW201201712A (en) 2010-01-28 2012-01-16 Max International Llc Compositions comprising sugar-cysteine products
WO2011149835A1 (en) 2010-05-24 2011-12-01 Max International, Llc Compositions and beverages comprising nutrients, vitamins, sugars, cysteine, and/or sugar-cysteine products

Also Published As

Publication number Publication date
US20090042822A1 (en) 2009-02-12
ES2390228T3 (es) 2012-11-07
EP1824481B1 (en) 2012-08-29
PL1824481T3 (pl) 2012-11-30
KR20070095900A (ko) 2007-10-01
CA2587616A1 (en) 2006-05-26
AU2005307885A1 (en) 2006-05-26
AU2005307885B2 (en) 2010-12-23
DK1824481T3 (da) 2012-09-24
JP2008520681A (ja) 2008-06-19
EP1824481A1 (en) 2007-08-29
BRPI0516814A (pt) 2008-09-23
MX2007005835A (es) 2007-10-08
WO2006055597A1 (en) 2006-05-26
US20160082029A1 (en) 2016-03-24
AU2005307885A2 (en) 2006-05-26
CA2587616C (en) 2015-03-17
US20130317072A1 (en) 2013-11-28
EA014076B1 (ru) 2010-08-30
CN101060840A (zh) 2007-10-24
US8501700B2 (en) 2013-08-06
US9144570B2 (en) 2015-09-29
US20060105972A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
EA200701017A1 (ru) Применение рибозы-цистеина для лечения гипоксии
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
WO2006034373A8 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
DK1780197T3 (da) 5-Substituerede 2-phenylamino-benzamider som MEK-inhibitorer
EA200870091A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для снятия боли
EA200500583A1 (ru) Ингибиторы белка-регулятора трансмембранной проводимости при муковисцидозе и их применение
NO20065079L (no) Materialer og metoder for behandling av koaguleringssykdommer
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
ATE543492T1 (de) Behandlung von lungenkrebs
CA2585266A1 (en) Ophthalmic compositions and methods of using the same
ATE424824T1 (de) Verfahren zur verhütung oder behandlung von herzarrhythmie
HK1099918A1 (en) Composition and use for prevention or treatment of stomatitis
EA200700433A1 (ru) Производные бетулинола в качестве агентов против вич (вируса иммунодефицита человека)
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis
ATE359798T1 (de) Verwendungvon dextransulfat zur behandlung von ibmir
CA2468664A1 (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
ATE429911T1 (de) Verwendung mindestens eines effektors des glutathionmetabolismus zusammen mit alpha- liponsäure zur immunmodulatorischen, abwehrsteigernden und/oder entzündungshemmenden behandlung
ATE431147T1 (de) Mittel zur behandlung des integrationsdysfunktionssyndroms
WO2006133231A3 (en) Treatment for neurodegenerative diseases
MX2009006670A (es) Composicion farmaceutica que usa el aliskiren y el avosentan.
ATE477021T1 (de) 1,3,5-triazepin-dionen zur behandlung von malaria
GB0229022D0 (en) Organic Compounds

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU